superficial bladder cancer- tcc · & nmp22 test (10/11) (74/79) cystoscopy 55% 86% alone (6/11)...
TRANSCRIPT
1
Superficial Bladder Cancer-TCC
Barry Stein, M.D.Professor Emeritus
Alpert Medical School ofBrown University
2009 data
Total of 70,980 new cases52,810 males18,170 females
Prevalence
Total is 14,300Men: 10,180Women: 4,150
Mortality
70,980 new pts annually
56,784 pts will have superficial tcc
39,750 will have a recurrence
7950 pts will upgrade or upstage
4,000 pts will develop metastases or die
Year 2 there would be 56,784 + 39,750 pts in the poolThis continues on ad infinitum
Plus any pts with upper tract tumors + bladder tumor
Breakdown of cases
Cause of TCC
Genetic Issues
• Genetic changes ie oncogenes play a role• Suppressor gene mutations ie
– P53- Ch 17– Rb- Ch 13q– 9p21 region of Ch 9
8
Patient Presentation
• Gross Hematuria in 85%• Microscopic hematuria• Pain on voiding• UTI• Incidental finding on CT or US study
The Hematuria “Tattoo”
Upper tract imagingCystoscopyCytologic exam
Work Up
• Upper tract imaging– CT scan – IVU
• Cystoscopy– Flexible– rigid
• Some type of “cytology” test• Then, after dx a tumor, a TURBT is
performed
CT Scan shows papillary lesion
CT Scan of Bladder Ca- solid
Upper Tract Tumor
Office Flexible Cystoscope
Rigid Cystoscopes
16
Superficial TCC- 80%
CIS (Flat Lesion)- 1-2%
Invasive Cancer- 20%
20
Let’s Talk About “Cytology”
AUA Guidelines 2001
Risk Factors
What’s the Trouble with Cytology?
• The following slides with comments on what’s the trouble with cytology are taken from a recent editorial in the Journal of Urology written by William Murphy
• Reference JU 176: 2343-2346, 2006
What’s the Trouble with Cytology?
• in my opinion the decades long dissatisfaction with UC as a method for detecting urothelial neoplasms can be condensed into the 3 somewhat related themes of
• 1) inaccurate histological classification and terminology
• 2) inappropriate clinical approach to urothelial neoplasms
• 3) lack of confidence among pathologists in general and cytopathologists in particular.
What’s the Trouble with Cytology?
• Many urological pathologists do not claim to have proficiency in cytology and many cytopathologists have not been specifically trained in urinary cytopathology.
• When assessing a urinary specimen, it is not uncommon for cytopathologists to attempt an extrapolation of criteria learned for uterine cervical lesions.
Urology 66, supplement 1, 35-63, 2005
• This paper studied:– 93 pts with known bladder cancer– 42 pts with benign disease– 50 normal volunteers– And compared BTA, NMP 22 and standard
urine cytology
29
Results:
30
Results- levels vs grade
31
32Compared: NMP22, BTA, telomerase activity, hgb dipstick and voided cytology
Results- compared to cysto and bx findings
33
34
Gupta et al – recurrence rates
35
Dogs trained to smell bladder cancer in urineMan's best friend could help fight disease,
scientists say
37
New Lab Test in development
Diagnosis DemographicsTotal Tested Population (1331) vs Patients with TCC (79)
TCC 79 / 1,331 (6%)
Sensitivity for Detecting TCC: Diagnosis
Cytology = 16%NMP22 Test = 57%
40
Improved Detection withNMP22 BladderChek Test and Cystoscopy
Muscle Invasive All Cancers
Cystoscopy 91% 94%& NMP22 Test (10/11) (74/79)
Cystoscopy 55% 86%alone (6/11) (68/79)
Cancers not seen by cystoscopy but detected by NMP22 Test:Bladder CIS, T2, T3; Ureter T2; Renal Pelvis T1, T3
P=0.014
Monitoring (Surveillance) Demographics
Total population = 668Patients with tumors = 103 (15%)
Sensitivity for Detecting Cancer: Monitoring
Cytology = 12%NMP22 Test = 50%
43
Improved Detection withNMP22 BladderChek Test and Cystoscopy
Muscle Invasive All Cancers
Cystoscopy 91% 99%& NMP22 Test (10/11) (102/103)
Cystoscopy 64% 91%alone (7/11) (94/103)
Cancers not seen by cystoscopy but detected by NMP22 Test:Ta G1, 2 Cis G3, T1 G3, 2 T2 G3, 2 T4 G3
P=0.005
Relative Risk- High Grade
Relative Risk- Low Grade
Bladder Cancer Detection AlgorithmResult: >99% Negative Predictive Value
Action: Standard SurveillancePathway
#1NMP22 Test(NEG)
Cystoscopy (NEG)
Pathway #2
NMP22Test (POS)
Cystoscopy (NEG)
Result: Potential for undetected cancer
Action: - More intensive investigation- Review/Schedule upper tract tests- Follow up within shorter interval
Pathway #3
NMP22Test (POS)
Cystoscopy (POS)
Result: - Up to 99% of cancers detected;- Elevated risk of muscle invasive
and/or high grade cancer
Action: Prioritize for biopsy
Pathway #4
NMP22 Test(NEG)
Cystoscopy (POS)
Result: Greater likelihood nonmuscle invasive and low grade cancer
Action: Standard biopsy
Pathway #2
NMP22Test (POS)
Cystoscopy (NEG)
Result: Potential for undetected cancer
Action: - More intensive investigation- Review/Schedule upper tract tests- Follow up within shorter interval
Pathway #3
NMP22Test (POS)
Cystoscopy (POS)
Result: - Up to 99% of cancers detected;- Elevated risk of muscle invasive
and/or high grade cancer
Action: Prioritize for biopsy
47
TreatmentSuperficial TCC
Initial Treatment
Staging
WHO Classification
Urology 66, supplement 1, 4-34, 2005
Papillary UN of LMP
Papillary Carcinoma LG
High Grade TCC
Progession Rates
Treatment Paradigm-IWhat is the risk of dying of this?
• Low risk of progression- 10%
• Ta- Grade 1• Ta- Grade 2• T1- Grade 1
Treatment Paradigm-II
• Moderate risk of progression- 25%
• Ta- Grade 3• T1- Grade 2
Treatment Paradigm-III
• High risk for progression- 50%
• T1- Grade 3• CIS
58
Intravesical Chemotherapy
• Indications:– Ablation– Prophylaxis– Prevent progression– CIS
• Agents:– BCG– MMC– Adriamycin– Interferon
60
At the end of the day…
• ~80% 5 yr survival rate for superficial ca– Most of the deaths are from Grade 3, T1
• ~60% 5 yr survival rate for invasive ca– We need earlier diagnosis and better
chemotherapy
61
Thank you for joining me.